Filter
835
Text search:
rifampicin
Featured
Recommendations
117
New Publications
238
Language
Document type
No document type
562
Guidelines
117
Studies & Reports
82
Manuals
28
Strategic & Response Plan
15
Fact sheets
13
Training Material
9
Situation Updates
4
Infographics
3
App
1
Resource Platforms
1
Countries / Regions
India
56
Western and Central Europe
55
Eastern Europe
32
South Africa
24
Nepal
23
Kenya
19
Namibia
17
Tanzania
16
Global
16
Nigeria
15
Germany
13
Zambia
13
Ethiopia
12
Uganda
12
Bangladesh
12
Malawi
10
Philippines
9
Myanmar / Burma
9
South–East Asia Region
9
Latin America and the Carribbean
9
Cambodia
8
Ukraine
8
Rwanda
7
Asia
7
Russia
6
Eswatini/ Swaziland
5
Africa
5
Tajikistan
5
Pakistan
4
Indonesia
4
Botswana
4
Ghana
3
Zimbabwe
3
Mozambique
3
Argentina
3
Colombia
3
Lesotho
3
Bhutan
3
Georgia
3
Sierra Leone
2
Liberia
2
Senegal
2
Syria
2
Benin
2
Sri Lanka
2
Eastern Europe and Central Asia
2
Armenia
2
Timor Leste/ East Timor
2
Burkina Faso
1
Congo, Democratic Republic of
1
Morocco
1
Saudi Arabia
1
Cameroon
1
Iraq
1
Jordan
1
Afghanistan
1
Lebanon
1
Thailand
1
Gambia
1
Malaysia
1
Sudan
1
Brazil
1
North Macedonia
1
Switzerland
1
Serbia
1
Ecuador
1
El Salvador
1
Greece
1
Libya
1
Madagascar
1
Yemen
1
Western Pacific Region
1
Paraguay
1
Fiji
1
Solomon Islands
1
North Korea
1
Albania
1
Laos
1
Romania
1
Iran
1
Uzbekistan
1
Kyrgyzstan
1
Kazakhstan
1
North America
1
Uruguay
1
Turkmenistan
1
Tunisia
1
Authors & Publishers
Publication Years
Category
Countries
303
Clinical Guidelines
106
Public Health
18
Women & Child Health
18
Capacity Building
15
Pharmacy & Technologies
12
Key Resources
10
Toolboxes
TB
365
HIV
78
NTDs
54
AMR
27
Pharmacy
25
Refugee
15
Polio
10
Ebola & Marburg
5
Mental Health
5
Caregiver
5
Conflict
4
COVID-19
4
Global Health Education
3
Natural Hazards
1
Health Financing Toolbox
1
Malaria
1
2.0 Rapid Response
1
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral
...
Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub5.
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med
...
This Rapid Communication aims to inform national TB programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.
Автоматизированная технология амплификации нуклеиновых кислот в режиме реального времени для быстрого и одновременного выявления туберкулеза и устойчивости к р
...
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral
...
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive
...
This document provides guidance on how to implement contact screening and chemoprophylaxis with single-dose rifampicin. The contents are logically ordered: counselling and obtaining consent, identification and listing of index case, listing of conta
...
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral
...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evi
...
The overall objective of this implementation plan is to define the strategy for implementation of the Xpert MTB/RIF test for rapid detection of TB and rifampicin (RIF) resistance in Tanzania, within the context of the National Tuberculosis and Lepro
...
Of the more than 10 million people estimated to have fallen ill with tuberculosis (TB) in 2022, just over 400 000 people developed TB resistant to rifampicin (RIF), and 1.3 million people developed TB resistant isoniazid (INH). Drug resistance must
...
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are need
...
The objective of the study was the validation and implementation of GeneXpert MTB/RIF for routine use in the rapid detection of tuberculosis and sensitivity to rifampicin in clinical samples; for this, 1592 respiratory samples were collected and ana
...
In 2019, an estimated 10 million individuals fell ill with tuberculosis (TB) and 3 million of them were not reported to have beendiagnosed and notified. The gap is proportionately even wider for drug-resistant TB. Of the estimated 465 000 patients with rif
...
Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim
...
